Since research has revealed the association of MYCN amplification with NB evolution [23, 24], independent from disease stage and age at diagnosis, MYCN amplification has been used as the biomarker for risk stratification [17, 25, 26]. The gene discussed is MYCN; the disease is neuroblastoma.